daizyluvr
Guest
I recently read the updates and changes to the Pathology/Laboratory NCCI policy manual pertaining to 88342 (IHC) specimen vs. block quantity and prostate biopsy billing codes. Is anyone familiar with the new guidelines of billing specimens vs. blocks for 88342 and billing the G0416 for >5 prostate specimens? I'm particulary interesting in finding information/resources that pertain to whether or not the major commercial payers are following those specific guidelines. The information I received from the insurance companies are that they follow Column 1/Column 2 CCI edits, Mutually Exclusive edits, and Medically Unlikely Edits. They won't say whether they are following the guidlelines for specimen quantity and charge determinations. Any help would be much appreciated!
Thank you
Thank you